Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patients with secondary acute myeloid leukemia undergoing allogeneic stem-cell transplant have inferior outcomes than de novo acute myeloid leukemia regardless minimal residual disease level by flow cytometry.
Núñez-Torrón Stock C, Jiménez Chillón C, Martín Moro F, Marquet Palomanes J, Velázquez Kennedy K, Piris Villaespesa M, Roldán Santiago E, Rodríguez Martín E, Chinea Rodríguez A, García Gutiérrez V, Moreno Jiménez G, López Jiménez J, Herrera Puente P. Núñez-Torrón Stock C, et al. Hematol Oncol. 2023 Oct;41(4):753-761. doi: 10.1002/hon.3160. Epub 2023 Apr 20. Hematol Oncol. 2023. PMID: 37081742
Real-life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single-centre experience.
Roldán Pérez A, Vázquez Paganini JA, Penalva Moreno MJ, Giménez Mesa E, Vilches Moreno AS, Nuñez-Torrón Stock C, Herráez García R. Roldán Pérez A, et al. Among authors: nunez torron stock c. Clin Case Rep. 2022 Jul 25;10(7):e6116. doi: 10.1002/ccr3.6116. eCollection 2022 Jul. Clin Case Rep. 2022. PMID: 35898750 Free PMC article.
Survival after allogeneic transplantation according to pretransplant minimal residual disease and conditioning intensity in patients with acute myeloid leukemia.
Núñez-Torrón Stock C, Jiménez Chillón C, Martín Moro F, Marquet Palomanes J, Piris Villaespesa M, Roldán Santiago E, Rodríguez Martín E, Chinea Rodríguez A, García Gutiérrez V, Moreno Jiménez G, López Jiménez J, Herrera Puente P. Núñez-Torrón Stock C, et al. Front Oncol. 2024 May 2;14:1394648. doi: 10.3389/fonc.2024.1394648. eCollection 2024. Front Oncol. 2024. PMID: 38756667 Free PMC article.